Publications by authors named "P Cherin"

Telomeres are ribonucleoprotein structures that form a protective buffer at the ends of chromosomes, maintaining genomic integrity during the cell cycle. A decrease in average telomere length is associated with with age and with aging-related diseases such as cancer and cardiovascular disease. In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.

View Article and Find Full Text PDF
Article Synopsis
  • Long-term adherence to chronic disease treatments is challenging, with only about 50% adherence in developed nations, prompting a need for effective management strategies.
  • The study evaluated how satisfaction with the Flexig mHealth application influenced adherence to subcutaneous immunoglobulin therapy among French patients with chronic dysimmune diseases over two years.
  • Results showed a high adherence rate of 99.7% linked to good user satisfaction with Flexig, indicating that digital tools can significantly enhance treatment compliance for patients.
View Article and Find Full Text PDF

The most common peripheral nervous system manifestations in Sjogren's syndrome are small fiber sensory neuropathies (SFPN) and axonal sensorimotor polyneuropathies. Currently, treatment in small fiber neuropathy is mainly symptomatic and based on anti-depressors and anti-epileptics. The benefit of treatment with polyvalent immunoglobulins for SFPN has been reported in small series of patients, although transient in several cases.

View Article and Find Full Text PDF

Background: Gaucher disease is a rare inborn error of lysosomal metabolism, characterized by lysosomal storage of the β-glucosylceramide. Bleedings observed in type-1 Gaucher disease (GD1) are commonly attributed to a low platelet count, but they can also occur when the platelet count is normal or slightly low. Abnormal platelet function has been described and deficiencies in coagulation factors too, such as factors II, V, VII, VIII, IX, X, XI, XII, and von Willebrand factor.

View Article and Find Full Text PDF
Article Synopsis
  • Immunoglobulins are used as secondary or tertiary treatments for dermatomyositis (DM) and polymyositis (PM) when corticosteroids and immunosuppressants fail, typically administered intravenously once a month or subcutaneously at home a few times a week.
  • A study involving seven patients (six with PM and one with DM) explored their experiences with both intravenous immunoglobulins (IVIg) and subcutaneous immunoglobulins (SCIg), revealing varied clinical profiles and significant improvements in symptoms after treatment.
  • Patients found SCIg to be more convenient and less disruptive to daily life compared to IVIg, allowing them to regain autonomy and control over their treatment while still being effective and well tolerated.
View Article and Find Full Text PDF